Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
Rhea-AI Summary
Propanc Biopharma (Nasdaq: PPCB) highlights preclinical and near‑term clinical plans for lead asset PRP, an investigational proenzyme therapy targeting metastatic solid tumors. Key points: >85% tumor growth inhibition in pancreatic models, FDA Orphan Drug status for pancreatic cancer, a $100M funding facility, new patents, and a planned Phase 1b first‑in‑human trial in 2026 for 30–40 advanced solid tumor patients.
The company positions PRP as a multi‑targeted approach that may sensitize tumors, reduce fibrosis and resistance markers, and potentially lower toxicity versus standard therapies.
Positive
- >85% tumor growth inhibition reported in preclinical pancreatic models
- FDA Orphan Drug status granted for pancreatic cancer
- $100M funding facility available to support development
- Phase 1b first‑in‑human trial planned in 2026 for 30–40 patients
Negative
- No large human efficacy data yet; clinical benefit remains unproven
- Compassionate rectal study limited: survival from ~5.6 to 9 months in advanced cases
- Preclinical results may not translate to human efficacy without positive clinical trials
News Market Reaction – PPCB
In the Mar 3 session, PPCB declined 5.16%, reflecting a notable negative market reaction. Argus tracked a peak move of +18.4% during that session. Argus tracked a trough of -21.4% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.8x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Corporate update & results | Neutral | -4.5% | Half-year results, asset summary, IP expansion and private placement facility details. |
| Feb 05 | PRP therapy spotlight | Positive | +5.7% | Highlighted PRP as game-changing therapy with strong preclinical data and large market. |
| Jan 27 | Provisional patent filing | Positive | +6.5% | Fourth provisional patent in two months strengthening PRP formulation IP and trial prep. |
| Jan 20 | New IP for Rec-PRP | Positive | -4.7% | Provisional patent on synthetic Rec-PRP production targeting metastatic cancer market. |
| Jan 15 | PRP preclinical overview | Positive | -17.1% | Detailed PRP preclinical efficacy, Orphan status, IPO funding and trial plans for 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows frequent sell-offs on positive or neutral news, with 3 divergences versus 2 aligned moves.
Over the last few months, PPCB has focused on expanding IP around its proenzyme therapy PRP, securing provisional patents and highlighting >85% tumor inhibition and Orphan Drug status. Corporate updates noted assets and financing facilities, while SEC filings emphasized losses, dilution, and going-concern risks. Market reactions have been mixed: several upbeat PRP and patent releases around Jan–Feb 2026 produced both rallies and sell-offs. Today’s preclinical highlight fits this narrative of strong scientific messaging against a challenged share-price backdrop.
Key Terms
epithelial-mesenchymal transition (EMT) medical
angiogenesis medical
tumor microenvironment medical
immunotherapies medical
orphan drug status regulatory
phase 1b medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRP May Outshine Traditional Therapies in a Booming
MELBOURNE, Australia, March 03, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today highlights the potential of its lead asset, PRP, as a novel therapeutic approach to the treatment and prevention of metastatic cancer from solid tumors, especially more aggressively spreading, less differentiated tumors, which offer a poor patient prognosis. Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate stuck at just
Standard treatments like chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel), targeted therapies (e.g., KRAS inhibitors), and emerging options (immunotherapies, tumor-treating fields like Optune Pax) extend life modestly but often bring harsh side effects, resistance, and limited success against this aggressive, metastasis-prone disease.
Enter Propanc's PRP—a promising investigational proenzyme therapy (trypsinogen + chymotrypsinogen in a 1:6 ratio) delivered intravenously. Unlike cytotoxic drugs that kill dividing cells broadly, PRP targets cancer stem cells, blocks metastasis by suppressing epithelial-mesenchymal transition (EMT), disrupts the tumor microenvironment, curbs angiogenesis, and boosts chemosensitivity—potentially making standard treatments more effective with far less toxicity.
Preclinical data shines: >
PRP vs. Current Treatment Options:
- Chemo: PRP could sensitize resistant tumors and cut doses/side effects.
- Targeted drugs: Broader attack on stem cells and spread, not just single mutations.
- Immunotherapy: May warm up “cold” pancreatic tumors by remodeling the microenvironment.
According to industry sources the global pancreatic cancer treatment market is valued at ~
Propanc is gearing up for a Phase 1b First-In-Human trial in 2026 (30–40 advanced solid tumor patients), backed by fresh funding (
“We are excited about PRP’s potential to transform cancer care by targeting the underlying mechanisms of metastasis with a mechanism that could offer meaningful advantages over existing therapies,” said James Nathanielsz, Propanc’s Chief Executive Officer. “PRP remains experimental—no large human efficacy data yet—but its multi-targeted, low-toxicity approach could redefine care for a disease desperate for breakthroughs,” Mr. Nathanielsz concludes.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
